Transurethral plasmakinetic resection of prostate for treatment of benign prostate hyperplasia: report of 131 cases

Objective: To assess the efficacy and safety of transurethral plasmakinetic resection of prostate(TUPKVP) for treatment of prostate hyperplasia.Methods: The clinical data of one hundred and thirty-one cases of symptomatic BPH treated by TUPKVP were analyzed retrospectively.Results: No severe hemorrhage or syndromes concerning the surgical procedure was observed.All the patients were followed up for 3 to 6 months.The average residual urine volume decreased from 120 ml to 14 ml;the average masimum flow rate increased from 8.5 ml/s to 21.5 ml/s;the average international prostate symptom score decreased from 23 to 5.5;and the average quality of life decreased from 5.1 to 1.6(P<0.01).No one developed permanent urinary incontinence.Conclusions: It suggests that TUPKVP has the advantages of high efficacy,high safety and less complication.It is worth popularizing.